RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1600 participants.
Also called NCT07187570
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,600 participants
- Registry
-
NCT07187570 -
2024-513719-28-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Sweden
- Registry status
- Recruiting
Technical summary
Registry record NCT07187570. Randomized; single masking; primary purpose treatment. Start 2025-06-03 (actual); primary completion 2027-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care
- Acronym
- RECUR-AF
- Condition
- Atrial Fibrillation (AF)
- Intervention (Drug)
- Dapagliflozin 10 mg once daily
- Lead sponsor
- Region Stockholm
- Collaborator
- Karolinska Institutet
Record details
- Record id
cardio:ct-nct07187570- Content hash
0c2a29338bf69dead9da6ab8122dcb40b995986a87746911bdbfe6203a2776bc